{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:49:23Z","timestamp":1794930563580,"version":"4.9.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373724"],"award-info":[{"award-number":["82373724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Henan Science and Technology Key project","award":["252102311220"],"award-info":[{"award-number":["252102311220"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The apelin\/APJ system represents a promising VEGF-independent therapeutic target for treating retinopathy of prematurity (ROP), given its selective upregulation in pathological retinal neovasculature. We aimed to identify clinically translatable APJ antagonists that suppress pathological neovascularization without VEGF-related side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We employed a hypoxia-induced zebrafish ROP model to recapitulate pathological neovascularization, combined with structure-based virtual screening of 2,506 FDA-approved drugs targeting the APJ receptor (PDB ID: 6KNM). Lead compounds were evaluated through\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      angiogenesis assays (human umbilical vascular endothelial cells [HUVEC] tube formation, migration, and invasion) and\n                      <jats:italic toggle=\"yes\">in\u00a0vivo<\/jats:italic>\n                      efficacy testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 21 initial hits, octreotide (\n                      <jats:bold>X-3<\/jats:bold>\n                      ) showed the most potent anti-angiogenic activity, with an IC\n                      <jats:sub>50<\/jats:sub>\n                      of 0.016 \u00b5M in HUVECs. Mechanistically,\n                      <jats:bold>X-3<\/jats:bold>\n                      selectively downregulated APJ expression without altering VEGF\/VEGFR levels. Functional assays confirmed its ability to suppress endothelial tube formation, migration, and invasion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings identified octreotide as a novel APJ antagonism with high translational potential, offering a dual advantage\u2014targeting pathological neovascularization while preserving physiological VEGF signaling. These findings support its repurposing as a precision therapy for ROP and other ocular neovascular disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683251389401","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:43:08Z","timestamp":1760542988000},"page":"139-147","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug Repurposing of Octreotide as a Selective Apelin Receptor Antagonist Against Pathological Angiogenesis: Integrated Virtual Screening and Zebrafish Validation"],"prefix":"10.1177","volume":"42","author":[{"given":"Yongfang","family":"Yao","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjun","family":"Song","sequence":"additional","affiliation":[{"name":"College of Chemistry and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Pingyuan Laboratory, Zhengzhou University, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000444901"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-019-0598-y"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.008"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.4161\/org.4.4.7414"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S94449"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.174847"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.05.004"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.8.47"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15602-3"},{"issue":"10","key":"e_1_3_4_11_2","first-page":"5313","article-title":"The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma","volume":"34","author":"Muto J","year":"2014","unstructured":"Muto J, , Shirabe K, , Yoshizumi T, et al. The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. Anticancer Res, 2014; 34(10):5313\u20135320.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0042-6822(03)00185-5"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201601074R"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201100069"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.08.105"},{"issue":"24","key":"e_1_3_4_16_2","first-page":"3263","article-title":"Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats","volume":"34","author":"Jin G","year":"2009","unstructured":"Jin G, , Yang P, , Gong Y, et al. Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats. Zhongguo Zhong Yao Za Zhi, 2009; 34(24):3263\u20133267.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111138"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.11.017"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30392"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-213X-7-114"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20203"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126750"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-1930fje"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683251389401","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251389401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683251389401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:15:01Z","timestamp":1787134501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683251389401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1177\/10807683251389401"],"URL":"https:\/\/doi.org\/10.1177\/10807683251389401","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}